We can't find the internet
Attempting to reconnect
19072.1 IP-LS
19072.1 IP-LS
Zusammenfassung
Development of neuroprotective molecules for the treatment of Amyotrophic lateral sclerosis (ALS)
Weitere Texte
Abstract
We have recently identified, using a drug-screening platform, a number of molecules that stimulate the activity of astrocytes, a type of glial cells that supports neuronal metabolism. These drugs, which improve neuronal survival and activity, are of particular interest for the treatment of neurodegenerative diseases. Most promising compounds are tested in a mouse model of ALS, as well as cognition/memory. The most effective candidates - whether neuroprotective or cognitive enhancers - will be patented and will represent the core of our Start-up pipeline
Beteiligte
Sylvain Lengacher
Wirtschaftspartner
sylengach@gliapharm.com
Gliapharm SA Sylvain Lengacher Ch. des Mines 9 1202 Geneva GE CH
Pierre Magistretti
Kontaktperson
pierre.magistretti@epfl.ch
EPFL Pierre Magistretti Station 19 1015 Lausanne VD CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2016-06-30
- Enddatum
- 2018-11-30
- Bewilligte Gesamtkosten
- CHF 313717.00
- Sektion
- 60 Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%